Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Company Description
Steinway Musical Instruments is a global manufacturer of musical instruments, as you may have guessed from the name. They also have some real estate leasing operations in New York.
Sales Up 6%
On May 9 the company reported first-quarter sales at $73 million, up 6% from last year. Unfortunately, earnings came in at $0.06 per share which was a penny less than expected. Earnings were weighed on by the real estate group, bringing EPS down 9 cents.
However, the company had encouraging things to say. "We are seeing a nice recovery and the steps taken to lean out our cost structure are having a noticeable effect on our results. We delivered solid growth in sales and gross margins, both domestically and overseas."
Enough for Analysts
On the earnings news analysts quickly raised their earnings outlook. The full-year consensus for 2011 jumped 22 cents, to $1.19. Next year's projections average $1.57, up 56 cents on the news. Last year Steinway made $0.67, putting forecasted growth rates at 77% and 32%, respectively.
Valuation Picture
Shares are trading at about 20 times the forward estimates right now. Not too bad, but the price to sales at 0.9 and price to book of 1.2 are showing a solid value. The PEG is pretty neutral, at 1.3 times.
Turning Around
Overall the earnings outlook has been flat for LVB over the past couple of years. However, we could be at the beginning of a resurgence. Given the highly discretionary market they are in, they should bounce back later in the overall economic recovery. Is that time now?
Bill Wilton is the Aggressive Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the Zacks Small Cap Trader service
Read the full reports :
Snapshot Report on LVB